Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Financing Activities (2024 - 2025)

Historic Cash from Financing Activities for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$285000.0.

  • Xilio Therapeutics' Cash from Financing Activities fell 940000.0% to -$285000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year change of. This contributed to the annual value of $29.2 million for FY2024, which is 54574.05% up from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' Cash from Financing Activities is -$285000.0, which was down 940000.0% from $47.4 million recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Cash from Financing Activities high stood at $47.4 million for Q2 2025, and its period low was -$285000.0 during Q3 2025.